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Introduction 
Epithelial ovarian cancer is the most lethal cancer among gynecologic cancers. The reason 
for this is the lack of symptoms in the early stage. Epithelial ovarian cancers are 
morphologically heterogeneous. Based on the cell type, ovarian cancers are divided into 
serous, mucinous, endometrioid, and clear cell (Prat, 2012). Compared to ovarian cancer, 
endometrial carcinoma (EC), as the most common gynecologic cancer, is highly curable 
due to its early diagnosis. Like ovarian cancer, the majority of endometrial cancers are 
sporadic and only 5% to 10% are familial. In endometrial carcinoma, Lynch syndrome is 
the most common hereditary cause, while in ovarian cancer, Lynch syndrome is the third 
common hereditary reason after BRCA1 and BRCA2 mutations (Ryan et al., 2005; Lynch 
et al., 2009).    
Since alteration in the DNA methylation status is known to be common in human cancer, 
DNA methylation pattern can be used as a diagnostic marker for cancer. One purpose of 
the present study was to detect the promoter DNA methylation patterns of four genes in 
clinical samples of sporadic ovarian cancer and precursor lesions of endometrial 
carcinoma. We aimed to study whether these genes can act as diagnostic markers for 
ovarian and endometrial cancers. 
Alterations in DNA methylation can be in the form of hypermethylation or 
hypomethylation. Hypermethylation can silence tumor suppressor genes and tumor 
suppressive microRNAs, while the activation of oncogenes and oncogenic miRNAs can 
be the result of hypomethylation (Sharma et al., 2010). For DNA methylation analysis, 
we used the methylation-specific multiplex ligation-dependent probe amplification (MS-
MLPA) assay. Unlike MS-MLPA, most common methods for DNA methylation analysis 
(MSP, qMSP, COBRA and bisulfite sequencing) are bisulfite conversion dependent, time 
and work consuming, and not suitable for paraffin-embedded tissue samples. The MS-
MLPA test, as a fast and easy method, can be applied successfully to paraffin-embedded 
tissue samples, which usually have poor quality (Nygren et al., 2005).  
Since a commercial MS-MLPA kit is available for a few genes known to be methylated 
in ovarian and endometrial carcinoma, a custom-made MS-MLPA test was designed to 
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analyze the methylation patterns of four genes associated with these carcinomas. Another 
purpose of this study was to validate the accuracy of the custom-designed MS-MLPA 
assay when applying to paraffin-embedded tissues. For testing optimum performance of 
custom-made test in DNA methylation detection, we applied the MS-MLPA test to the 
cancer and normal cell lines and healthy control DNA samples and compared the findings 
with bisulfite sequencing results.  
The selected genes were HNF1 homeobox B (HNF1β), Ten-eleven translocation 
1(TET1), L1 cell adhesion molecule (L1CAM), and AT-rich interactive domain 1A 
(ARID1A). In L1CAM and ARID1A genes, two islands were studied. First, the promoter 
DNA methylation status of these genes were analyzed in 20 cancer and normal cell lines 
and DNAs using bisulfite sequencing and the MS-MLPA assay. As both results were 
comparable, the custom-designed MS-MLPA test was performed on ovarian and 
endometrial cancer samples.  
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Review of the literature  
1. Cancer  
 
Cancer has traditionally been considered a group of related diseases that develop due to 
the accumulation of genetic mutations (Hanahan &Weinberg, 2000). However, the 
importance of cancer epigenetics has been increasingly highlighted recently. Six 
hallmarks are considered for cancer by Hanahan and Weinberg (2000). Maintaining 
chronic proliferation is the first hallmark of cancer. Normal tissues undergo controlled 
proliferation, while abnormal proliferation in cancer cells results in the development of 
tumors. As the second hallmark of cancer, due to the inactivation of tumor suppressor 
genes, cells continue to grow and proliferate without any limitations which can result in 
evolving cancer. The third hallmark of cancer is evasion of apoptosis. Programmed cell 
death is required to prevent cancer development. Cancer cells with resistance to 
programmed cell death can succeed in progressing to tumors. As another hallmark of 
cancer, unlimited replication is required for cancer cells to produce tumors. An ability to 
induce blood-vessel formation is required for cancer cells, not just to supply oxygen and 
nutrients, but to remove metabolic waste products and carbon dioxide. Tissue invasion 
and metastasis, the sixth hallmark of cancer, is the spread of cancer to another organ 
(Hanahan & Weinberg, 2000). 
In 2011, Hanahan and Weinberg added two new hallmarks to their list, including an 
abnormal energy pathway and evading immune surveillance. Normal tissues, under 
normal conditions, utilize aerobic oxidative phosphorylation to generate energy, while 
cancer cells undergo aerobic glycolysis to produce energy. This glycolytic switch can 
result in the activation of oncogenes and mutation in tumor suppressor genes. Evading 
immune surveillance is the eighth hallmark of cancer. The immune system plays an 
important role in resisting the formation of tumors. Cancer cells, by escaping immune 
surveillance can succeed in developing to tumors.  Genomic instability and chronic 
inflammation are the underlying hallmarks that enable these eight hallmarks to develop 
and result in tumor progression (Hanahan & Weinberg, 2011).  
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1.1. Cancer genetics 
 
Cancer can arise from the accumulation of genetic alterations including base 
substitutions, deletions, insertions, amplifications, alterations in chromosome number, 
and chromosome translocations (Lengauer et al., 1998). These alterations are mostly 
sporadic. Three types of cancer related genes, including oncogenes, tumor suppressor 
genes, and stability genes, are responsible for tumorigenesis (Vogelstein & Kinzler, 
2004). 
 
1.1.1. Oncogenes, tumor suppressor genes, and DNA mismatch repair genes 
 
Proto-oncogenes play a key role in regulating cell growth and differentiation. When 
proto-oncogenes are mutated or highly expressed, they can predispose to cancer genes 
called oncogenes. Oncogene activation by stimulation of cell birth or the inhibition of cell 
death can lead to tumorigenesis. One somatic mutation is sufficient for the activation of 
oncogenes. Oncogenes can be activated due to chromosomal translocation, gene 
amplification, and subtle intragenic mutation. Tumor suppressor genes are responsible for 
inhibiting cell growth. Unlike oncogenes, if they are not expressed because of a mutation, 
increased proliferation and tumor development result.  According to the two-hit 
hypothesis, inactivation of both alleles in a tumor suppressor gene is essential for 
tumorigenesis (Vogelstein & Kinzler, 2004). 
DNA mismatch repair (MMR) genes are responsible for recognizing and repairing the 
base-base mismatches and insertion/deletion mispairs that occur during DNA replication. 
Of the MutS-related proteins, MSH2-MSH3 and MSH2-MSH6 complexes are required 
for mismatch recognition, while MLH1-PMS2 and MLH1-MLH3 are two complexes of 
MutL-related proteins responsible for recognizing mismatches. Germline mutations in 
mutL homologue 1 (MLH1), mutS homologue 2 (MSH2), MSH6, or postmeiotic segrega-
tion increased 2 (PMS2) can cause Lynch syndrome. Like tumor suppressor genes, 
mutations in two alleles are required for defective mismatch repair (Peltomäki, 2014). 
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1.1.2. Genomic instability in cancer  
 
Genomic instability as a characteristic of cancer has various forms, including 
chromosome instability (CIN) and microsatellite instability. In chromosome instability, 
chromosome structures and numbers change over time in a cancer cell population 
(Negrini et al., 2010). Microsatellite instability (MSI) is caused by deficiencies in DNA 
mismatch repair (MMR) genes. The mismatch repair pathway is responsible for 
correcting replication errors that occur during DNA replication in microsatellite 
sequences (Sameer et al., 2014). 
 
1.1.2.1. Chromosome instability (CIN) 
 
Since the majority of cancers display chromosome instability (CIN), it has been 
considered a predominant hallmark of cancer. The definition of chromosome instability 
is the elevated rate of changed in karyotypes in a cell population. CIN, as the main form 
of genomic instability, can be divided into numerical CIN and structural CIN. Numerical 
CIN is the gain or loss of a whole chromosome, causing aneuploidy, while Structural CIN 
is abnormality in structure of chromosomes, resulting in translocation, deletions, and 
amplifications of DNA. In practice, due to several reasons, measuring CIN is difficult. 
The loss of accurate molecular methods to profile cell to cell variability, difficulty in 
detecting chromosomal aberrations over time, and the diversity of chromosomal 
aberrations are the challenges in measuring CIN (Heng et al., 2013).  
CIN plays an important role in cancer because it can either contribute to cancer or 
suppress tumor development. In hereditary cancers, CIN can cause cancer development 
by inducing mutations in DNA repair genes. In sporadic cancer, two models can explain 
the role of CIN: the mutator hypothesis and oncogene-induced DNA replication stress 
model. The mutator hypothesis emphasizes the rarity of mutation in normal cells and the 
frequency of spontaneous mutations in cancer cells. Although in sporadic cancer the 
molecular basis of genomic instability is not clear, the latter model states that oncogene 
activation can cause deregulated DNA replication (Negrini et al., 2010). 
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1.1.2.2. Microsatellite instability (MSI)  
 
Microsatellite instability (MSI) is an alteration of the length in repetitive genomic 
sequences due to insertions or deletions and is caused by mutations in DNA mismatch 
repair (MMR) genes (Sameer et al., 2014). MMR is as one of the repair mechanisms that 
recognizes and repairs small DNA loops. Mutated MMR genes can fail in repairing errors 
in repetitive sequences, which results in MSI. Although MSI can be seen in tumors of 
different organs, it is considered as a marker of Lynch syndrome and colorectal cancer 
(Kurzawski et al., 2004). MSI caused by deficient MMR genes is a hallmark of LS tumors 
but it is also detected in about 15% of sporadic CRCs (Dionigi et al., 2007).  
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1.2. Cancer epigenetics 
 
Epigenetics has been defined as ‘‘the study of changes in gene function that are 
mitotically and/or meiotically heritable and that do not entail a change in DNA sequence’’ 
(Riggs & Porter, 1996). Epigenetic abnormalities play an important role in the promotion 
of cancer development, in addition to genetic alterations (Jones & Baylin, 2007). 
Epigenetic mechanisms can be divided into four categories: DNA methylation, histone 
modification, noncoding RNAs, including microRNAs (miRNAs), and chromatin 
remodeling (Wong et al., 2007, Wilson & Roberts, 2011). The interplay of these 
mechanisms regulates the genome by regulating its accessibility and compactness 
(Sharma et al., 2010). 
 
1.2.1. DNA methylation 
 
DNA methylation as the best known epigenetic mechanisms plays a key role in the 
regulation of gene transcription. Alterations in DNA methylation in the form of site-
specific hypermethylation or genome-wide hypomethylation can contribute to 
carcinogenesis (Das and Singal, 2004). Although about 70% of all CpG dinucleotides are 
methylated in the human genome, CpG dinucleotides within CpG islands are mostly 
unmethylated during development and in normal tissues (Kim et al., 2009). Methylation 
of CpG islands has been identified as the gene silencing mechanism that has a key role in 
regulation of gene expression and chromatin structure. In the mammalian genome, DNA 
methyltransferases (DNMTs) is responsible for adding a methyl group to the position 5 
carbon on the cytosine (C) nucleotide, most commonly at the 5’-CG-3’ dinucleotides. 
Several DNMTs have been identified, including: DNMT1, DNMT1b, DNMT1o, 
DNMT1p, DNMT2, DNMT3A, DNMT3b with its isoforms, and DNMT3L. The other 
mechanisms involved in DNA methylation are demethylases, methylation centers, and 
methylation protection centers (Das and Singal, 2004). 
Hypomethylation, which is a loss of methylation in the 5-methylcytosine nucleotide, has 
typically been found in all neoplasms. Hypomethylation can contribute to carcinogenesis 
by several mechanisms. First, hypomethylation in repetitive sequences, such as satellite 
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or pericentromic regions, can result in genomic instability. In addition, hypomethylation 
of retrotransposons can result in abnormal gene structure and function. Hypomethylation 
can also contribute to the activation of oncogenes. Finally, hypomethylation can lead to 
a loss of imprinting, resulting in gene expression imbalances and cancer development. 
Hypermethylation, as an important event in developing cancer, can lead to the repression 
of transcription in tumor suppressor genes, mismatch repair genes, and cell-cycle-
regulatory genes at CpG islands and contribute to gene silencing. It also can result in a 
loss of imprinting in cancer (Wong et al., 2007). 
  
1.2.2. Histone modification, Chromatin remodeling and microRNA 
 
Chemical modifications of histone such as methylation, acetylation, phosphorylation, and 
ubiquitinylation, can modify the chromatin structure from inactive heterochromatin to 
active euchromatin, and vice versa (Wong et al., 2007). Depending upon the type of 
residues and chemical modifications, histone modifications can either activate or repress 
gene promoters. For example, histone methylation can either have repressive or activating 
effect on chromatin depending on the methylated amino acid residue, while histone 
acetylation usually activate transcription (Ferrari et al., 2014). Nucleosome remodeling, 
as a non-covalent mechanism, has a key role in the regulation of gene activity. Mutations 
in remodelers, which use ATP hydrolysis to alter chromatin structure, can cause cancer 
development. MicroRNAs (MiRNAs) are small non-coding endogenous RNAs that not 
only regulate gene expression at a post-transcriptional level, but also play a key role in 
epigenetic mechanisms. Epigenetic modifications can affect microRNAs expression, and 
microRNAs also have the capacity to control the epigenome (Sharma et al., 2010).  
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2. Lynch syndrome  
 
Lynch syndrome, which is traditionally known as hereditary nonpolyposis colorectal 
cancer (HNPCC), is an autosomal dominant disorder caused by inherited aberration in 
the DNA mismatch repair (MMR) system and is associated with tumors with 
microsatellite instability (MSI). People with Lynch syndrome have a high risk of 
developing colorectal, endometrial, ovarian and some other cancers (Aarnio et al., 1999). 
Mismatch repair genes, including MSH2, MSH6, MSH3, MSH4, MSH5, MLH1, PMS2, 
PMS1, and MLH3, are responsible for repairing mistakes made during DNA replication 
in humans. Inherited defects in MMR genes, mutL homologue 1 (MLH1), mutS 
homologue 2 (MSH2), MSH6, or postmeiotic segregation increased 2 (PMS2) can cause 
Lynch syndrome (Lynch et al., 2009).  
DNA MMR genes can be inactivated by either genetic or epigenetic mechanisms. 
Inactivation of both alleles in DNA MMR genes is required for tumor development. In 
hereditary cancer, mutation in one allele is inherited and the second allele is inactivated 
in the somatic cell, while in sporadic cancer, inactivation of both alleles occurs 
somatically. Epigenetic mechanisms play a fundamental role in Lynch syndrome by 
inactivating tumor suppressor genes or causing epimutations in MMR genes. MMR genes 
can be inactivated by epigenetic events, including constitutional epimutations as the first 
hit and promoter methylation as the second hit (Peltomäki, 2014).  
The first diagnostic criteria for Lynch syndrome diagnosis was the Amsterdam criteria. 
According to the classic Amsterdam criteria, a Lynch syndrome family contains three or 
more individuals with a Lynch syndrome-associated cancer in 2 generations at an age of 
less than 50 years (Stoffel et al., 2009).  The Bethesda guidelines were developed in 1997 
and revised in 2003 for the genetic diagnosis of Lynch syndrome. The Bethesda 
guidelines for Lynch syndrome recommend microsatellite instability (MSI) testing or 
abnormal immunohistochemistry (IHC) of the tumors from individuals with HNPCC. 
According to several studies, the Bethesda guidelines are the most accurate (94%) 
guidelines, followed by the Amsterdam criteria II (72%) and classic Amsterdam criteria 
(61%) (Umar et al., 2004).  
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As many Lynch syndrome families do not fulfill Amsterdam criteria or Bethesda 
guidelines, or they meet these two guidelines but they do not have germline mutations in 
any DNA MMR genes, the Jerusalem criteria were developed in 2010. According to 
these guidelines, all CRCs diagnosed at an age of 70 or younger, should be screened by 
MSI or IHC testing (Boland & Lynch., 2013).  
Since the basic epigenetic patterns are specific to tissue types, methylation changes 
observed in Lynch tumors are essentially expected to resemble those seen in the 
corresponding sporadic tumors (Nieminen et al., 2016). Therefore, knowledge of 
epigenetic patterns obtained by studying Lynch-associated endometrial and ovarian 
tumors is likely to be valid for their sporadic counterparts and vice versa. This aspect will 
be further discussed in later sections (e.g. Conclusions and future prospects, p.59) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
 
3. Ovarian cancer 
 
Ovarian cancer is the sixth most common cancer in women. It accounts for 6.1 cases per 
100, 000 women and its lifetime risk is 0.5 %( Bogliolo et al., 2016). Ovarian cancer is 
the most lethal gynecological cancer, as it causes over 100, 000 deaths per a year among 
women worldwide (Prat, 2012). The reason for the high mortality rates is the late 
diagnosis in most cases (Jayson et al., 2014). Most cases of ovarian cancer are sporadic 
and only 5% to 10% of cases are familial. There are different risk factors for ovarian 
cancer. A family history of the disease, BRCA1 and BRCA2 mutations, and Lynch 
syndrome are the most significant risk factors for ovarian cancer (Holschneider & Berek, 
2000).  
Epithelial ovarian cancer is a heterogeneous cancer that is classified into five main groups 
based on histopathology and molecular genetics. These five distinct types are high-grade 
serous, endometrioid, clear cell, mucinous, and low-grade serous. High-grade and low-
grade serous are different tumor types, and are the most and the least common types of 
ovarian cancer, respectively (Prat, 2012). In another classification, ovarian cancer is 
classified into type I and II tumors. Type I tumors, which are low grade, include 
endometrioid, mucinous, and clear cell type. Type I tumors contain mutations in BRAF, 
KRAS, and PTEN with microsatellite instability. Type II tumors are high grade, including 
high-grade serous and carcinosarcoma. Mutations in p53, BRCA1, and BRCA2 are 
frequently detected in type II tumors (Jayson et al., 2014). 
High-grade serous carcinomas (HGSCs), as the most common and lethal types of ovarian 
cancer, are characterized by p53 gene abnormalities and deleterious mutations in BRCA1 
and BRCA2. Additionally, genomic instability and DNA copy number abnormalities 
have been detected in the most high-grade serous cancer. Low grade serous carcinomas 
(LGSC) are uncommon and exhibit KRAS and BRAF mutations. Unlike HGSCs, LGSCs 
are not related with BRCA1 and BRCA2 germline mutations. It has been proposed that 
both HGSC and LGSC arise from distal fallopian tube (Prat, 2012).  
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Mucinous ovarian cancers have KRAS mutations and a high frequency of HER2 
amplification (Jayson et al., 2014). In clear-cell carcinomas (CCCs), mutations in the 
ARID1A gene are prevalent (Prat, 2012). Upregulation of HNF1B has been identified in 
CCCs (Kato et al., 2007). Endometrioid ovarian cancers account for 10% of all ovarian 
carcinomas. This carcinoma has been reported more in patients with Lynch syndrome 
compared to other types of ovarian cancer. ARID1A mutations and somatic mutations of 
the beta-catenin (CTNNB1) and PTEN genes are the most prevalent abnormalities in 
endometrioid carcinomas. Most CCCs and ECs seem to originate from ovarian 
endometriosis (Prat, 2012).  
 
3.1. Lynch syndrome-associated ovarian cancer 
 
In women with Lynch syndrome, ovarian cancer can be the presenting cancer or a second 
cancer. Women with Lynch syndrome have a higher risk (6-8%) of developing ovarian 
cancer than the 1.4% risk in the general population. Compared to the general population, 
a younger diagnosis age (42-48) has been reported for Lynch syndrome-associated 
ovarian cancer. Lynch syndrome accounts for 10-15% of hereditary ovarian cancer cases. 
Unlike sporadic ovarian cancer, which is mostly diagnosed in stage III or IV, 80% of 
Lynch syndrome-associated ovarian cancers are diagnosed in stages I or II. 
Histologically, ovarian cancers in Lynch syndrome have a non-serous type (Nakamura et 
al., 2014). Ketabi et al. (2011) focused 0n 63 Swedish and Danish families with Lynch 
syndrome-associated ovarian cancer and found a variety of histopathological subtypes 
including, endometrioid (35%), serous (28%) and clear cell (17%). Bonadona et al. (2011) 
studied 537 French families with Lynch syndrome and found a 20% lifetime risk of 
ovarian cancer for MLH1 mutation carriers, 24% for MSH2 and 1% for MSH6. They 
concluded that the lifetime risks for ovarian cancer is mostly associated with MLH1 or 
MSH2 mutations.  
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4. Endometrial cancer 
 
Endometrial carcinoma (EC) is the most common gynecologic cancer and it accounts for 
15-20 cases per 100, 000 women per year. The lifetime risk for this cancer is 2.7% and 
the median age of diagnosis is 65 years. Endometrial cancer is highly curable due to its 
early diagnosis. Most of the endometrial cancers (90%) are sporadic and only 10% are 
familial (Ryan et al., 2005). The majority of familial endometrial cancer are associated 
with hereditary non-polyposis colorectal cancer (HNPCC). The risk factors for 
endometrial cancer are family history, estrogen exposure, older age, obesity, early 
menarche, late menopause and infertility (Burke et al., 2014).  
Sporadic endometrial cancers are morphologically heterogeneous and are divided into 
two groups based on histological features; estrogen-dependent adenocarcinoma (type I) 
with endometrioid morphology and estrogen-independent carcinoma (type II) with serous 
papillary and clear cell morphology. The first group, which are more common (90% of 
ECs), are tumors that occur in pre- and post-menopausal women and have a good 
prognosis. Type I tumors are usually low grade and are associated with abnormalities in 
DNA-mismatch repair (MMR) genes, K-ras, PTEN and beta-catenin. The second group 
consists of tumors that occur in post-menopausal women and they usually show highly 
aggressive clinical behaviors. Type II tumors are commonly associated with 
abnormalities of p53 and HER2/neu (Ryan et al., 2005).  
For both of type I and type II endometrial adenocarcinoma, precursor lesions are known: 
endometrial hyperplasia, which is the precursor of endometrioid adenocarcinoma, and 
endometrial intraepithelial carcinoma (EIC), which is the precursor of serous and clear 
cell carcinomas. Endometrial hyperplasia can be classified into simple hyperplasia with 
and without cytologic atypia, and complex hyperplasia with and without cytologic atypia. 
Endometrial hyperplasia with atypia is the least common type but is the type most likely 
to develop to endometrial (Type I) carcinoma. Simplex hyperplasia rarely develop to 
endometrial carcinoma (Wang et al., 2015).  
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4.1. Lynch syndrome-associated endometrial cancer 
 
The majority of inherited endometrial carcinomas are associated with Lynch syndrome. 
Women with Lynch syndrome with MLH1 or MSH2 mutation has a risk of 40% of 
developing endometrial cancer. The median age at which women with Lynch syndrome 
are diagnosed with endometrial cancer is 49 years. Lynch syndrome-associated 
endometrial cancers primarily have an endometrioid histology, but other types, including 
clear cell, papillary serous and MMMT, have been reported (Nakamura et al., 2014). 
Bonadona et al. (2011), by studying 537 French families with Lynch syndrome, found a 
54% lifetime risk of endometrial cancer for MLH1 mutation carriers, 21% for MSH2 and 
16% for MSH6. In another study of 155 women with Lynch syndrome-associated 
endometrial cancer, Stoffel et al. (2009) found a lifetime risk of 39.39% for MLH1 or 
MSH2 mutation carriers. These results indicated that lifetime risks for endometrial cancer 
are mostly associated with MLH1 or MSH2 mutations.  
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5. Methods to study methylation 
 
There are different methods for studying DNA methylation as a common epigenetic 
change in mammals. These approaches can be divided into two main groups: global DNA 
methylation analysis and gene-specific methylation analysis. High-performance liquid 
chromatography (HPLC) is a highly quantitative method to quantify global DNA 
methylation. In this method DNA is first hydrolyzed and, then, the 5 methylated cytosines 
(5 mC) and deoxycytidine (dC) are separated chromatographically and the methylation 
levels are measured by comparing the relative absorbance of cytosine and 
methylasytosine. This method is limited by requiring a large amount of DNA and not 
being suitable for high-throughput analysis (Fraga & Esteller, 2002). Global DNA 
methylation can also be assessed by bisulfite-based PCR methods. These methods are 
based on bisulfite treatment of DNA and PCR products of repetitive DNA elements, such 
as Alu elements and long interspersed nucleotide elements (LINE). Unlike HPLC, 
bisulfite-based PCR methods require very little DNA. Methylated DNA 
immunoprecipitation (MeDIP) is a genome-wide method for the determination of 
methylation patterns. In this high-resolution method, anti-methylcytosine is used to 
immunoprecipitate DNA containing highly methylated CpG sites. Then, 
immunoprecipitated DNA is hybridized to a microarray. Like HPLC, a large amount of 
genomic DNA is required in this method (Shen& Waterland, 2007).  
There are several gene-specific approaches to studying DNA methylation. In 
methylation-specific PCR (MSP), PCR is performed by using two sets of primers that are 
able to amplify either methylated or unmethylated alleles. MSP is a highly sensitive 
method that can even be applied to paraffin-embedded tissues with poor quality, but is 
not a quantitative method. Quantitative methylation-specific PCR (qMSP) is a 
quantitative method of MSP, which is frequently used to detect the amount of methylation 
at specific loci. Compared with MSP, in this method, a reference sequence in a separate 
reaction is required for assay optimization (Shames et al., 2007). Combined bisulfite 
restriction analysis (COBRA) is a quantitative technique for methylation detection. In this 
method, after bisulfite treatment and PCR amplification, PCR products are treated with a 
restriction enzyme and digested fragments are finally separated by polyacrylamide gel 
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electrophoresis. Unlike MSP, this method is time consuming and the analysis can only be 
done for specific restriction enzyme cutting sites. Bisulfite-pyrosequencing is another 
method for DNA sequencing. In Bisulfite-pyrosequencing chemical light reaction is used 
to detect the incorporation of nucleotides into the single stranded DNA. A molecule of 
pyrophosphate (PPi) is released from incorporated nucleotides into the strand, and 
converted to ATP. ATP provides the energy for a light reaction in which luciferin is 
converted to oxyluciferin by luciferase. Light is captured and visualized graphically 
(Shames et al., 2007). Illumina Infinium HumanMethylation 450 BeadChip (450K) is an 
array based profiling approach for DNA methylation detection on a genome-wide scale. 
This array contains480, 000 probes, and targets 99% of genes and 96% of CpG islands 
(Marabita et al., 2013). Bisulfite sequencing developed by Frommer et al (1992) is 
regarded as a gold-standard technology for profiling the DNA methylation status. In this 
methods, after bisulfite modification, unmethylated cytosines are converted to uracil 
whereas methylated cytosines remain unaffected. In subsequent PCR, the region of 
interest is amplified in both methylated and unmethylated alleles. After PCR 
amplification, DNA can be sequenced to quantify DNA methylation status (Li et al., 
2011).  This method is described in more detail below (Figure 1 and page 36). As most 
methods for analyzing DNA methylation status are based on bisulfite conversion and 
require a great amount of high-quality DNA, Methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA) was developed to analyze  methylation status 
and copy number changes of genomic DNA (Nygren et al., 2005). 
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5’ –TGGGCTGCCCGGGGGCCCCCAGCCCAAGCCGCGCTCG- 3’ 
3’ –ACCCGACGGGCCCCCGGGGGTCGGGTTCGGCGCGAGC- 5’ 
 
 
 
5’ –TGGGUTGUUCGGGGGUUUUUAGUUUAAGUCGCGUTCG- 3’ 
3’ –AUUUGAUGGGCUUUUGGGGGTUGGGTTUGGCGCGAGC- 5’ 
 
 
 
5’ –TGGGTTGTTCGGGGGTTTTTAGTTTAAGTCGCGTTCG- 3’ 
3’ –ATTTGATGGGCTTTTGGGGGTTGGGTTTGGCGCGAGC- 5’ 
 
 
 
 
 
 
 
 
 
 
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bisulfite converted 
Bisulfite PCR 
 
TGGGTTGTTCGGGGGTTTTTAGTTTAAGTCGCGTTCG 
Sequencing data analysis 
 
 
Figure1. Outline of bisulfite sequencing. In bisulfite conversion of genomic 
DNA, unmethylated cytosine residues (black) are converted to uracil, while 
methylated cytosines (blue) remain unaffected. In subsequent PCR, uracil residues 
are converted to thymine. DNA methylation pattern can be detected by PCR 
sequencing. 
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5.1. The MS-MLPA method 
 
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) is a 
method to detect simultaneously changes in the gene copy number and methylation status 
of up to 40 chromosomal sequences using only 20 ng of genomic DNA. MS-MLPA 
probes contain a methylation sensitive HhaI recognition site (GCGC). In this method, 
after genomic DNA denaturation and MS-MLPA probes hybridization, the probe-DNA 
complex is ligated and digested by a methylation-sensitive enzyme. If the CpG site is 
methylated, a normal MS-MLPA signal will be produced. If the CpG island is not 
methylated, the genomic DNA-MS-MLPA probe complex will be digested by Hha1 and 
no amplification will take place. The major advantage of this method compared with other 
methods, such as MSP and bisulfite sequencing, is that it is not based on bisulfite 
conversion of unmethylated cytosines. Moreover, this very quantitative method allows 
for a combined copy number and DNA methylation detection in a single reaction. 
Furthermore, MS-MLPA can be performed on poor quality DNA, such as DNA from 
formalin fixed, paraffin-embedded tissues. Formaldehyde fixation and embedding in 
paraffin result in partial denaturation and degradation of the DNA, which do not influence 
the results in MS-MLPA test. Despite the many advantages, the MS-MLPA test has also 
been criticized. For example, methylation sites must contain a restriction site (GCGC) for 
the methylation-sensitive HhaI enzyme (Nygren et al., 2005). The principal of this 
method is described in more detail below in Figure 2 and page 39.  
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M 
M 
Methylated target 
Denaturation and multiplex 
probe hybridization 
 
LPO 
 
 
 
Ligation and digestion 
PCR with universal primers 
(only ligated probes are amplified) 
 
Fragment analysis 
 
*  
*  
M 
LPO RPO 
M 
RPO 
*  
LPO 
Figure 2. Outline of MS-MLPA procedure. MS-MLPA probes contain 
two oligonucleotides, Left probe oligonucleotide(LPO) and right probe 
oligonucleotide(RPO). Both oligonucleotides harbor universal primer sites 
(orange), optional stuffer sequence (blue), and hybridizing sequence 
(black). MS-MLPA probes contain a methylation-sensitive restriction site 
(GCGC=  ) for HhaI. MS-MLPA Probe-DNA complex is simultaneously 
ligated and digested by methylation specific enzymes. If the CpG residues 
in the GCGC site is methylated, a normal MS-MLPA peak will be detected. 
If the CpG site is not methylated, MS-MLPA probe-DNA complex is 
digested by the HhaI and no signal will be detected. In the fragment analysis 
part, the top picture is the MS-MLPA results without HhaI treatment. The 
lower panel is the reults after digestion with HhaI. As it can be seen, there 
is no signal for ARID1A,4 and ARID1A,5 in the lower picture, indicating 
that the CpG site is not methylated in ARID1A. (    = control peaks). 
*  
Unmethylated target 
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6. Genes included in the custom MS-MLPA test 
 
6.1. The HNF1B gene 
 
Hepatocyte nuclear factor-1beta (HNF-1 beta), also known as transcription factor 2 
(TCF2), is a member of the homeodomain-containing superfamily of transcription 
factors. This gene is located at chromosome 17q12 and composed of 9 coding exons. 
HNF1B has a major role in endodermal development (Nemejcova et al., 2016). In 
humans, HNF1B expression is tissue specific in normal tissues, which is most likely 
controlled at the epigenetic level (Kato et al., 2007). This gene has was observed to be an 
excellent marker for clear cell carcinoma (CCC) of the ovary (Tsuchiya et al., 2003).  
Terasawa et al. (2006) studied HNF1B as a target for epigenetic inactivation in ovarian 
cancer. They examined the promoter methylation status of HNF1B in 15 ovarian cancer 
cell lines and 98 ovarian cancer specimens using combined bisulfite restriction analysis 
(COBRA). They found that eight (53%) of the ovarian cancer cell lines were heavily 
methylated at HNF1B promoter. In clinical ovarian cancer samples, HNF1B was 
methylated in 41.3% of serous samples, 25.0% of mucinous tumors, and 28.6% of 
endometrioid tumors. No methylation was detected in clear cell samples and normal 
ovarian tissues. They concluded that differences in the DNA methylation patterns 
between clear cell and other types of ovarian cancer may be a useful diagnostic marker.  
To assess the correlation between the methylation and expression status, they used RT-
PCR to check the gene expression of 15 ovarian cancer cell lines. Expression of HNF1B 
was not detected in any of the eight methylated cell lines, concluding a direct link between 
DNA methylation and gene silencing.   
Cuff et al. (2013) characterized HNF1B promoter methylation in ovarian serous and clear 
cell histotypes. Among four ovarian serous cases, all of them exhibited methylated 
patterns, while in each of three ovarian clear cell carcinoma cases, no DNA methylation 
was detected. The relation between HNF1B promoter methylation and gene expression 
was previously reported in ovarian carcinoma (Terasawa et al., 2006). Cuff et al. (2013) 
concluded that as there is a direct link between DNA hypomethylation of HNF1B and its 
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expression in ovarian clear cell carcinoma, it can be used as a marker of clear cell 
phenotype.  
Tsuchiya et al. (2003) analyzed 12,600 genes to identify genes associated with ovarian 
clear cell carcinoma, using the oligonucleotide array method. Sixteen genes were up 
regulated in CCC including HNF1B. They validated the over expression of HNF1B in 
mRNA and protein level using real-time quantitative reverse transcriptase-polymerase 
chain reaction and immunoblotting. Furthermore, immunohistochemical expression of 
HNF1B was analyzed in 83 ovarian cancer specimens including 22 CCC and 61 non-
CCC specimens. Of 22 CCC cases, 21 showed immunostaining, while most non-CCC 
cases (60 of 61) were negative immunohistochemically. They concluded that the 
expression of HNF1B was strongly linked to ovarian clear cell carcinoma.  
In another study, Shen et al. (2013) analyzed expression and DNA methylation patterns 
of HNF1B in serous ovarian cancer in The Cancer Genome Atlas (TCGA) Research 
Network. The results showed that HNF1B was epigenetically silenced in half the 576 
serous ovarian tumors, while there was no evidence of methylation in normal fallopian 
tube samples. 
To identify the relation between the methylation and expression status, they analyzed 
immunohistochemical expression of HNF1B in 1,149 ovarian cancers from the Ovarian 
Tumor Tissue Analysis Consortium, and DNA methylation patterns of 269 of these 
samples. Unmethylated, expressed HNF1B was detected in the majority of the CCC 
tumors, whereas the majority of serous tumors were immunohistochemically negative for 
HNF1B and showed frequent methylation of this gene. A direct link between the DNA 
methylation and protein expression was concluded.  
Shen et al. (2013) also studied the promoter DNA methylation patterns of HNF1B in 32 
serous and 4 clear cell ovarian tumors using the Illumina Infinium Human methylation 
27 assay. The promoter region was methylated in 42% of serous cases and methylation 
of HNF1B was not detected in none of the clear cell ovarian tumors. This opposite manner 
of HNF1B in serous and CCC ovarian cases supported the hypothesis that HNF1B may 
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have a tumor suppressor role in serous cancer and an oncogenic role in clear cell ovarian 
cancer.  
Nemejcova et al. 2016 analyzed HNF1B expression immunohistochemically in lesions of 
the endometrium in 320 cases including both tumor and non-tumor endometrial lesions. 
The expression of HNF1B was detected in 28% of endometrial endometrioid carcinoma 
(ECs), 26% of serous carcinoma, 83% of endometrial clear cell carcinoma, 95% of 
ovarian clear cell, 88% of hyperplasia with atypias, 91% of hyperplasias without atypias, 
and ≥ 80% of different normal endometrium samples.  
They also examined the methylation patterns of HNF1B in 30 endometrial endometrioid 
cases, 19 ovarian clear cell carcinomas, and 15 corresponding normal endometrium 
tissues.  Promoter DNA methylation was detected in 13.3% (4/30) of endometrioid ECs, 
whereas there was no evidence of DNA methylation in normal endometrium and in 
ovarian CCC. They concluded that the strong expression of HNF1B in CCCs compared 
to other subtypes can be helpful as a marker for ovarian CCC phenotype.   
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6.2. The L1CAM gene 
 
The L1 cell adhesion molecule (L1CAM) is an axonal glycoprotein belonging to a large 
class of immunoglobulin superfamily cell adhesion molecules (CAMs) that is responsible 
for cell-to-cell adhesion. L1CAM is involved in the development of the nervous system 
(Kenwrick et al., 2000). The aberrant expression of L1CAM has been observed in many 
human tumors and is correlated with aggressive tumor behavior (Kato et al., 2009).  
Kato et al. (2009) studied the L1CAM gene promoter methylation status and its protein 
expression pattern in 4 CRC cell lines and 71 primary CRCs.  Of 4 CRC cell lines, 2 
(SW480 and SW620) showed strong expression of L1CAM protein, whereas expression 
of L1CAM protein was not detected in two other CRC cell lines (Caco-2 and DLD-1). 
They also examined the expression of L1CAM in 71 patients with primary CRCs. Normal 
colonic epithelium were negative for the L1CAM expression and 31 (43.7%) of 71 
carcinoma cases were histochemically positive. They concluded that L1CAM expression 
is regulated by epigenetic modification in CRC cell lines, and that DNA hypomethylation 
in the L1CAM CpG islands is correlated with L1CAM aberrant expression and 
contributes to aggressive behavior of tumors in CRC.  
Huszar et al. (2009) analyzed the expression of the L1CAM in 272 endometrial 
endometrioid carcinoma cases and identified 29% of cases (78 of 272) were L1CAM 
positive and 71% (194 of 272) were L1CAM negative. They also examined the expression 
of the L1CAM in the mixed ECs cases composed of endometrioid and serous or clear-
cell cases. The mixed ECs cases were L1CAM positive. These results suggested that 
normal endometrium and the majority of endometrioid ECs are L1CAM negative, 
whereas L1CAM was strongly expressed in serous and clear cell ECs. They concluded 
that immunohistochemical analysis of endometrioid ECs might be useful for the 
identification of patients with this type of tumors that have a bad prognosis.   
Schirmer et al. (2013) examined the possible correlation between DNA methylation and 
protein expression of the L1CAM promoter in endometrial carcinomas (ECs) using RT-
PCR, Western blotting and bisulfite sequencing. They investigated 6 endometrial 
carcinomas (ECs) cell lines and identified a low level of expression in 4 of 6 cell lines 
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(ECC1, HEC1A, EN1, MFE 296), while 2 of them were highly expressed ( HEC1B and 
SPAC1L). They also studied the promoter methylation status of L1CAM in two promoter 
regions, one before the non-translated exon (exon 0) and one next to the first coding exon 
(exon 1). They identified that the cell lines with positive results in expression (HEC1B 
and SPAC1L) showed the lowest level of methylation in promoter 1, whereas a high level 
of methylation was detected in negative cell lines in expression. They concluded that 
promoter 1 methylation status is correlated with the level of L1CAM expression. They 
also studied the methylation of the L1CAM promoter in EC tumor tissues. They found a 
high variability in L1CAM promoter methylation and no marked differences were 
detected in promoter methylation of expression-positive and expression-negative 
samples.  
In serous ovarian carcinoma, L1CAM expression in tumors and ascitic fluid associates 
with a highly invasive and metastatic propersity (Bondong et al., 2012). We are not aware 
of any published studies examining the relationship between L1CAM expression and 
methylation in endometrial hyperplasias or subtypes of ovarian carcinoma.  
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6.3. The TET1 gene  
 
Ten-eleven translocation 1 (TET1), as a part of the TET protein family (TET1, TET2, and 
TET3), is a dioxygenase that plays an important role in cytosine demethylation. TET1 
functions as a tumor suppressor gene in tumor cells (Hsu et al., 2012). 
Ichimura et al. (2015) studied the DNA methylation and expression patterns of the TET1 
gene in colorectal cancer, using bisulfite pyrosequencing, qRT-PCR, and western blot 
analysis. A high level of DNA methylation was detected in three of six colorectal cancer 
cell lines (SW480, RKO, and HT29), and there was no TET 1 expression in these three 
cell lines. Meanwhile, the other three cell lines (LS174T, SW480, and LOVO) showed a 
low level of DNA methylation correlated with TET1 expression. They found that DNA 
methylation of the TET1 gene is correlated with silencing of TET1. They also examined 
TET 1 expression in tumor and normal tissues from colorectal cancer cases. TET1 down-
regulation was significantly detected in cancerous tissues compared to normal tissues.  
CpG island methylator phenotype (CIMP), a phenotype with an extensive CpG island 
promoter methylation, has mostly been studied in colorectal cancer (Hughes et al., 2013). 
Ichimura et al. (2015) also examined the expression level of the TET family genes in 
CIMP-positive and CIMP-negative colorectal cancer tissues. TET 1 was significantly 
down-regulated in CIMP-positive colorectal cancer cases (23/55, 42%) compared to 
CIMP-negative cases (2/113, 2%).  
Li et al. (2016) analyzed TET1 the DNA methylation and expression status in multiple 
cancer cell lines and primary tumor samples. For example, 27% (3/11) of primary colon 
carcinomas showed TET1 promoter methylation by methylation-specific PCR and 
methylation was associated with reduced mRNA expression by semi-quantitative reverse 
transcription-PCR. The results demonstrated that there is a direct link between promoter 
CpG methylation and TET1 inactivation. They concluded that the tumor-specific 
methylation of TET1 could serve as an epigenetic marker.  
In one study, Hsu et al. (2012) indicated that TET1 is downregulated in prostate and breast 
cancer tissues and TET1 inhibits prostate and breast cancer invasion and metastasis. To 
 32 
 
our knowledge, TET1 methylation has not been addressed in endometrial hyperplasia or 
ovarian cancer, so far. 
 
6.4. The ARID1A gene 
 
ARID1A (AT-rich interactive domain 1A) gene is a tumor suppressor gene located at 
Ch1P36.11 and encodes a DNA-binding protein called BAF250a. ARID1A is a subunit 
of the SWI/SNF adenosine triphosphate-dependent chromatin-remodeling complexes. 
SWI/SNF complexes play an essential role in tissue development, differentiation and 
tumor suppression (Reisman et al., 2009). Frequent mutations of ARID1A has been 
discovered in ovarian clear cell carcinoma (Jones et al., 2010). Somatic inactivating 
mutations of ARID1A and loss of its expression occur most frequently in endometrium-
derived tumors, including ovarian clear cell carcinomas, ovarian and uterine endometrioid 
carcinomas (Mao & Shih., 2013). 
Zhang et al. (2013) examined the correlation between ARID1A hypermethylation and 
mRNA expression in breast cancers. They analyzed promoter methylation of 38 pairs of 
breast invasive ductal carcinoma and their normal breast tissues using MeDIP-qPCR. 
Low mRNA expression was detected by real time RT-PCR in 22 out of 38 (57.9%) 
cancerous tissues. In this low expression group, 19 of 22 (86.4%) samples showed 
ARID1A promoter hypermethylation. They came to the conclusion that promoter 
hypermethylation is the main reason for low expression of ARID1A mRNA in invasive 
ductal carcinomas.  
 
 
 
 
 
 
 33 
 
Aims of this study 
As several studies have shown that there is a connection between aberrant DNA 
methylation status and human cancers, the first aim of this study was to design a custom-
made MS-MLPA assay to investigate alterations in DNA methylation in endometrial and 
ovarian tumors. Four genes associated with ovarian and endometrial cancers in the 
literature were selected to be examined (HNF1B, TET1, L1CAM, and ARID1A). The 
study material consisted of sporadic ovarian cancer (79 cases), endometrial hyperplasias 
(59 cases), normal endometrium (18 cases) and normal fallopian tube (14 cases). The 
promoter methylation status of the selected genes were analyzed using a custom-designed 
MS-MLPA test. 
Another purpose of this study was to evaluate if the custom-made MS-MLPA test would 
work properly on the clinical samples. Since the clinical samples are usually formalin-
fixed, paraffin-embedded, they have poor quality. As currently the majority of methods 
for DNA methylation analysis are not suitable for paraffin-embedded tissues, MS-MLPA 
test could serve as powerful tool for DNA methylation profiling in paraffin-embedded 
tissues where small amounts of DNA are available. 
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Material and methods 
1. The cell lines used in bisulfite sequencing studies  
 
Fifteen cancer cell lines and five normal cell lines and healthy control DNA samples, 
listed in Table 1, were obtained from the American Type Culture Collection (Rockville, 
USA) before this study and used in this study for bisulfite sequencing.   
 
Table 1. Cell lines used for bisulfite conversion studies.  
Name of the 
  cell lines         
Tissue of origin & disease                  Name of the 
  cell lines 
Tissue of origin & disease 
ES2  
OV4   
SKOV3  
CAOV3   
AN3CA 
HCA7    
KM12 
RKO   
T84  
HCT15 
Ovary, clear cell adenocarcinoma     
Ovary, serous adenocarcinoma    
Ovary, serous adenocarcinoma    
Ovary, serous adenocarcinoma    
Uterus/endometrium adenocarcinoma    
High methylator colorectal carcinoma 
Colon, adenocarcinoma      
High methylator colorectal carcinoma 
Colon, colorectal carcinoma  
High methylator colorectal carcinoma                                                                                                                                                                                                   
HCT116  
SW480   
BT-549  
CAL-51     
ZR-75-1    
MCF-12A   
TKF 
SPR.198  
Normal uterus    
Normal colon                          
Colon, colorectal carcinoma    
Colorectal adenocarcinoma  
Hypermethylator breast cancer cell 
Breast cancer cell with MSI 
Low methylator breast cancer cell       
Normal breast epithelial cells    
Blood 
Blood    
Epithelial 
Epithelial
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2. Tumor and normal samples used in MS-MLPA studies 
As listed in Table 2, the study material consisted of sporadic ovarian tumors (n = 79, 
including 24 endometrioid, 35 clear cell, and 20 high-grade serous tumors) and precursor 
lesions of endometrial carcinoma (n = 59, including 19 sporadic complex atypical 
hyperplasia, 17 sporadic simplex hyperplasia, and 23 sporadic complex hyperplasia). 
Reference group included 18 normal endometrium and 14 normal fallopian tissues.  
 
Table 2. Number of patient samples used in this study. 
   Sample name                                                                               Sample number 
   Precursor lesions of endometrial carcinoma 
         Sporadic complex atypical hyperplasias                                       
         Sporadic simplex hyperplasia                                                    
         Sporadic complex hyperplasia                                                                                                          
   Sporadic ovarian cancer 
          Sporadic serous ovarian cancer                                                                              
          Sporadic endometrioid ovarian cancer                                 
          Sporadic clear cell ovarian cancer                                        
  Normal samples 
          Normal endometrium tissues                                               
          Normal fallopian tissues                                                     
 
19 
17 
23 
 
20 
24 
35 
 
18 
14 
 
 
3. DNA extraction 
 
Genomic DNA from cancer and normal cell lines and DNAs had been previously isolated 
using the method of Lahiri et al. (1991) before this study. DNA from paraffin-embedded 
tumor samples had also been previously isolated according to the modified protocol of 
Isola et al. (1994).  
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4. Bisulfite sequencing 
 
Bisulfite sequencing is a method for determining DNA methylation. In this method, DNA 
is first treated with sodium bisulfite, during which the unmethylated cytosines are 
converted to uracils and 5-methylcytosines remain as cytosines. Then, converted DNA is 
amplified by PCR using bisulfite primers. After bisulfite conversion, the two strands of 
DNA are no longer complementary. Thus, both methylated and unmethylated sequences 
will be amplified.  In the PCR reaction, 5-methylcytosines are amplified as cytosines and 
the uracils are amplified as thymines. Finally, the PCR product is sequenced to quantify 
the DNA methylation status (Clark et al., 2006). 
 
4.1. Bisulfite conversion of DNA 
 
Altogether, 600 ng of genomic DNA was used for bisulfite conversion of DNA, in which 
unmethylated cytosine is deaminated to produce uracil in DNA, and methylated cytosines 
are protected from this conversion and remain as cytosines. All the cell lines, including 
15 cancer cell lines, three normal cell lines and two normal DNA samples, were bisulfite 
converted. To perform bisulfite treatment, the EZ DNA Methylation-Gold Kit was used, 
as described by the manufacturer (Zymo Research, Orange, CA, USA). 
 
4.2. Bisulfite primer design and PCR of bisulfite-converted DNA  
 
As the primer design is critical for successful bisulfite PCR, special attention was given 
to the following primer designing guidelines. The primers should design so that the target 
promoter region contains one or more HhaI recognition site which later are needed for 
the MS-MLPA probe design. Bisulfite PCR primers should design longer than normal 
PCR primers (26-30), and the amplicon size should be relatively short (190 bp to 217 bp). 
Preferably, primers should not contain CpG sites in their sequences. Usually, an annealing 
temperature between 55-60 °C works well. To identify the promoter regions for any CpG 
islands, the EMBOSS CpGplot program 
(www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/index.html) and the MethPrimer 
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(www.urogene.org/methprimer) were used. All the studied promoter regions located on 
the CpG islands, except L1CAMI. The L1CAM gene has two active promoter sites 
(Promoter 1 and 2). Promoter 1 was studied here. In the ARID1A gene, two CpG islands 
were studied.  
Bisulfite converted DNA was amplified using the following protocol: initial denaturation 
at 95 °C for 5 minutes, 35 cycles of denaturation (30 seconds at 94 °C), annealing for 30 
seconds (variable Tm for each gene), extension (30 seconds at 72 °C), and at the end, a 
final extension at 72 °C for 5 minutes. In the bisulfite PCR amplification, uracil is 
recognized as thymine and unmethylated cytosines are recognized as cytosines, allowing 
methylated and unmethylated cytosines to be distinguished. The reaction mix used for 
bisulfite PCR amplification and the bisulfite primer sequences are described in Table 3 
and 4, respectively. The resulting PCR fragments were visualized by 2% agarose gel 
electrophoresis. After the gel separation, the PCR products were purified using ExoSAP-
IT® PCR Clean-Up reagent (Usb®, USA, 78200), in which excess primers and dNTPs 
were eliminated from the PCR product. After purification, the PCR products were 
sequenced with an Applied Biosystems ABI 3730 Automatic DNA Sequencer. 
 
Table 3. The reaction mix used in bisulfite-PCR reactions. 
Constituent   concentration                       Manufacturer Volume (µl) Final concentration 
10X PCR buffer(containing 15mM Mgcl2) 
dNTP mixture     
Forward primers (5 µM) 
Reverse primers (5 µM) 
HotStar Taq DNA polymerase (5 units/µl) 
Distilled water 
Template of bisulfite converted DNA       
Total volume                                                                             
QIAGEN 
Finnzymes 
Sigma-Aldrich 
Sigma-Aldrich 
QIAGEN  
2,5 
0,5 
2 
2 
0,25 
Variable 
Variable 
25 
1X 
200 µM 
0.4 µM 
0.4 µM 
1.25 units/reaction 
- 
0.05-0.15 µg/ 25 µl 
- 
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Table 4. Primers used in bisulfite-PCR reactions. 
Gene Primers sequences Tm Size References 
HNF1B 
 
TET1 
 
L1CAM, island I 
 
L1CAM, island II 
 
ARID1A, Island 4   
       
ARID1A, Island 5  
F: 5’- GGGGTYGAGTTYGATATTAAGT-3’ 
R: 5’- TACCTAAACATCCRATCCACCT-3’ 
F: 5’- AGGGTTGGTGTAGGTTTGGAGTT-3’ 
R: 5’- AAAACRAACCCACCCCTAAAACAA-3’ 
F: 5’- TTAGAGAGTTGGAGGAAAATTTG-3’ 
R: 5’- ACACACACACACAAAACAAAAC-3’ 
F: 5’- GTTTTAGGTTTTTGGGAGTATTTT- 3’ 
R: 5’- CACCCTAACCCCTAATACCAAC- 3’ 
F: 5’- GTTGTTAGGGGGTTAGGGTTG- 3’ 
R: 5’- CCTTCCCTTCACAAAAAAAA- 3’ 
F: 5’- GTTTGGGGGGAATGAGTYGGGAG- 3’ 
R: 5'- TCCCCCRAACTACCCTCCCCAC- 3' 
52 
52 
60 
60 
58 
58 
58 
58 
60 
60 
64 
64 
191 bp 
 
220 bp 
 
261 bp 
 
225 bp 
 
297 bp 
 
217 bp 
Terasawa et al. 2006 
Terasawa et al. 2006 
This     study 
This     study 
Schirmer et al. 2013 
Schirmer et al. 2013 
This     study 
Schirmer et al. 2013 
This     study 
This     study 
This     study 
This     study 
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5. MS-MLPA  
 
5.1. MS-MLPA probe design 
 
MS-MLPA probes were designed for HNF1B, L1CAM, TET1, and ARID1A as described 
in the guidelines, Designing synthetic MLPA probes (MRC-Holland, the Netherland, 
version 10). Each designed probe contained at least one HhaI restriction site in the target 
recognition sequence (Figure 3). Custom-designed MS-MLPA probe sets are described 
in Table 5. CpG islands in the selected genes were identified using the EMBOSS CpGplot 
and MethPrimer programs. All of the designed MS-MLPA probes were located in the CpG 
islands of the analyzed genes, except L1CAMI. Structures of promoter CpG islands for 
the studied genes are depicted in Figures 4-7 below. 
Each MS-MLPA probe consists of two separate oligonucleotides, including the left probe 
oligonucleotide (LPO) and the right probe oligonucleotide (RPO). Both oligonucleotides 
contain a universal primer sequence, hybridizing sequence, and an optional stuffer 
sequence that is used when needed to modulate the total probe length. Each MS-MLPA 
probe contains a recognition site for the methylation-sensitive restriction enzyme. For 
example, Hhal restriction enzyme recognizes GCGC sites. 
 
 
Figure 3. MS-MLPA probe components (source:  Designing synthetic MLPA probes instructions, MRC-
Holland, the Netherlands). 
  
(includes GCGC) 
 Target Sequence includes GCGC 
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When designing MS-MLPA probes, specific attention was given to following guidelines. 
In each MS-MLPA reaction, there should be at least a total of 5 unique probes in a 
probemix to obtain reliable results, and there should not be more than 11 synthetic probes 
in a reaction. LPO and RPO should locate directly adjacent to each other, and the 
minimum length of each should be 21 nucleotides. Each designed probe should have a 
unique total amplicon length. The optimal probe length is between 100 and 140 
nucleotides, as long probes will produce a lower signal and they will often have shoulder 
peaks. There should be a space of at least 4 nucleotides between two probes. The 
minimum Tm for each hybridizing sequence is 68 °C, and preferably Tm should be higher 
than 71 °C. Preferably, the secondary structure (ΔG) for each probe should be positive, 
although some probes with negative ΔG work.  Details on probe sequences are shown in 
Table 6. 
 
5.2. The MS-MLPA assay and data analysis 
 
MS-MLPA was performed as described by the manufacturer (MRC-Holland, 
Amsterdam). MS-MLPA reagents were purchased from MRC-Holland, Amsterdam, and 
the Netherlands. Approximately 150 ng of genomic DNA was denatured for 10 min at 98 
°C. SALSA MLPA buffer (1.5 µl ), reference probes (1 µl), and designed probes (0.5 µl) 
were then added, and after incubation for 1 min at 95 °C , were allowed to hybridize to 
their respective target for about 16 h at 60 °C. After hybridization, the mixture was diluted 
at room temperature with H2O and 3 µl ligase buffer A to a final volume of 20 µl and then 
equally divided between two tubes. In one tube, half of the sample was ligated using H2O 
(8.25 µl), ligase buffer B (1.5 µl), and ligase-65 enzyme (0.25 µl), whereas in the second 
tube, ligation was combined with Hhal digestion replacing Hhal enzyme with H2O. PCR 
was performed by the addition of 5 µl of the PCR mixture containing H2O (3.75 µl), 
SALSA primer mix (1 µl), and SALSA polymerase (0.25) to the ligation mixture. PCR 
products were diluted in water and mixed with internal size standard (LIZ Sixe) and 
deionized formamide, and separated by capillary gel electrophoresis and quantified using 
Genemapper software (Applied Biosystems).  
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MS-MLPA data was analyzed in Microsoft Excel as described by the manufacturer’s 
guideline (MRC-Holland, Amsterdam). To quantify the methylation status of each GCGC 
site the peak area of each probe is first divided by the combined value of the control 
probes within the samples generating relative peak values. Then, the relative peak values 
of the digested sample are divided by those of the corresponding undigested sample. This 
number is the methylation ratio, Dm (Nygren et al., 2005). 
For a meaningful interpretation of the methylation data, the Dm values were used to 
determine two important thresholds, first, the technical threshold for methylation and 
second, the threshold for hypermethylation. The former describes the ability of the MS-
MLPA method to detect methylation when compared to bisulfite sequencing (see p.44).  
Hypermethylation refers to increased methylation in tumor DNA compared to the 
corresponding normal DNA. The threshold for hypermethylation was defined for each 
gene individually and calculated as the average Dm plus one standard deviation (if this 
value was lower than the technical threshold, the technical threshold was used instead, 
see p. 50).   
 
5.3. Statistical analysis 
Statistical analysis were conducted using SPSS software, version 24.0 (IBM SPSS Inc. 
Chicago, IL, USA). Fisher’s exact test was used to calculate two-sided p values for 
pairwise comparisons of hypermethylation frequencies between groups. P values < 0.05 
were considered significant.  
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Table 5: Target sequence of probes used for the custom-made MS-MLPA test. 
Gene Location within CpG islands Probe target sequence with HhaI site in bold                        Distance of  HhaI  site from 
coding ATG (bp)* 
 
HNF1B 
 
TET1 
 
L1CAM, island I 
 
L1CAM, island II 
 
ARID1A, Island 4   
       
ARID1A, Island 5  
Yes 
 
Yes 
 
No 
 
Yes 
 
Yes 
 
Yes 
 
(LHS)GACGACTATGACACACCTCCCATCCTCAAG-
(RHS)GAGCTGCAGGCGCTCAACACCGAGGAG 
(LHS)CCGGGAGGCGGCGCTCGGCGCGGGCTGGAT-
(RHS)GTGGCGGGCTCTGCGTCCTTGGCTCTCC 
(LHS)CCTGGGCTCGCCTCCTACCCTGCCGCCCAC- 
(RHS)CTGGGCTCTGGGGTGCGCAGGAGCCGGTGC 
(LHS)GGGCTGCCCGGGGGCCCCCAGCCCAAG-
(RHS)CCGCGCTCGGCTGGCACCAGGGGCTAGGGT 
(LHS)CGGGAGGGGACAGACCTGGATAGGGACG-
(RHS)CCGGGAGGGAGGCGGCGCAGGCTCCAGA 
(LHS)CCTACAGAGCCGGGAGCAGCTGAGCCGC- 
(RHS)CGGCGCCTCGGCCGCCGCCGCCGCCTCCT 
+286 
 
−11514 & −11507 
 
−10927 
 
−10479 
 
−900 
 
−227 
 LHS: Left hybridizing sequence/ RHS: Right hybridizing sequence. 
* Plus sign indicates an upstream location whereas a minus sign denotes a downstream location. 
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Table 6. Probe design for the custom-made MS-MLPA test (detailed characteristics). 
Gene GC % 
 
Tm °C 
 
ΔG 
kcal/mol 
Probe sequences      
HNF1B 
 
TET1 
 
L1CAM, island I 
 
L1CAM, island II 
 
ARID1A, Island 4          
       
ARID1A, Island 5 
53 % 
67 % 
68 % 
58 % 
77 % 
77 % 
85 % 
77 % 
68 % 
79 % 
71 % 
90 % 
76 
81.9 
97 
91 
89.95 
90.84 
93.96 
90.34 
83.21 
90.75 
84.47 
96.63 
1.88 
0.89 
– 1.01 
0.98 
– 0.11 
– 0.31 
– 1.82 
0.41 
0.47 
0.69 
0.65 
– 1.65 
LPO: 5' GGGTTCCCTAAGGGTTGGACATCTTGAGTCCATCTTGAGTCCATCTGACGACTATGACACACCTCCCATCCTCAAG 3' 
RPO: 5' GAGCTGCAGGCGCTCAACACCGAGGAGTTCATGGTTCATGGTTCATGGTTCATTCTAGATTGGATCTTGCTGGCAC 3' 
LPO: 5' GGGTTCCCTAAGGGTTGGA CATCTTGACCGGGAGGCGGCGCTCGGCGCGGGCTGGAT 3' 
RPO: 5' GTGGCGGGCTCTGCGTCCTTGGCTCTCCTTCATGTCTAGATTGGATCTTGCTGGCAC 3' 
LPO: 5' GGGTTCCCTAAGGGTTGGACATCTTGAGTCCACCTGGGCTCGCCTCCTACCCTGCCGCCCAC 3' 
RPO: 5' CTGGGCTCTGGGGTGCGCAGGAGCCGGTGCTTCATGGTTTCTAGATTGGATCTTGCTGGCAC 3' 
LPO: 5' GGGTTCCCTAAGGGTTGGACATCTTGAGTCCATCTTGAGTCGGGCTGCCCGGGGGCCCCCAGCCCAAG 3' 
RPO: 5'CCGCGCTCGGCTGGCACCAGGGGCTAGGGTTTCATGG TTCATTCTAGATTGGATCTTGCTGGCAC 3' 
LPO: 5' GGGTTCCCTAAGGGTTGGACATCTTGAGTCCATCTTGAGTCCATCGGGAGGGGACAGACCTGGATAGGGACG 3' 
RPO: 5' CCGGGAGGGAGGCGGCGCAGGCTCCAGATTCATGGTTCATGGTTCATGTCTAGATTGGATCTTGCTGGCAC 3' 
LPO: 5' GGGTTCCCTAAGGGTTGGACATCTTGAGTC CATCTTGAGTCCCTACAGAGCCGGGAGCAGCTGAGCCGC 3' 
RPO: 5' CGGCGCCTCGGCCGCCGCCGCCGCCTCCTTTCATGGTTCATGGTTCATCTAGATTGGATCTTGCTGGCAC 3' 
LPO: Left probe oligo, RPO: Right probe oligo 
PCR primer binding sequence (bold), stuffer (italic), hybridizing sequence (underlined), and HhaI site (bold italic) 
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Figure 4: Structure of L1CAM promoter CpG island. CpG sites are shown as vertical lines. Bisulfite 
sequencing region (BS-F and BS-R) analyzed and MS-MLPA probe containing GCGC site (  ) are also 
indicated. The first coding exon is depicted as a separate box consisting of white box indicating untranslated 
region and the gray portion representing the translated region. Translation initiation site (ATG) is located 
at the start of the gray portion. 
Reference for publication with the evidence for the importance of the chosen region for methylation analysis: Schirmer, 
U., Fiegl, H., Pfeifer, M., Zeimet, A., Müller-Holzner, E., Bode, P., . . . Altevogt, P. (2013). Epigenetic regulation of 
L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens. BMC Cancer, 13, 1-12). 
 
 
Figure 5: Structure of HNF1B promoter CpG island. CpG sites are shown as vertical lines. Bisulfite 
sequencing region (BS-F and BS-R) analyzed and MS-MLPA probe containing GCGC site (  ) are also 
indicated. The first coding exon is depicted as a separate box consisting of white box indicating untranslated 
region and the gray portion representing the translated region. Translation initiation site (ATG) is located 
at the start of the gray portion. 
Reference for publication with the evidence for the importance of the chosen region for methylation analysis: Terasawa, 
K., Toyota, M., Sagae, S., Ogi, K., Suzuki, H., Sonoda, T., … Tokino, T. (2006). Epigenetic inactivation of TCF2 in 
ovarian cancer and various cancer cell lines. British Journal of Cancer, 94(6), 914–921. 
 
* 
*  
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Figure 6: Structure of TET1 promoter CpG island. CpG sites are shown as vertical lines. Bisulfite 
sequencing region (BS-F and BS-R) analyzed and MS-MLPA probe containing GCGC sites (  ) are also 
indicated. The first coding exon is depicted as a separate box consisting of white box indicating untranslated 
region and the gray portion representing the translated region. Translation initiation site (ATG) is located 
at the start of the gray portion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Structure of ARID1A promoter CpG island. CpG sites are shown as vertical lines. Bisulfite 
sequencing region (BS-F and BS-R) analyzed and MS-MLPA probe containing GCGC site (  ) are also 
indicated. The first coding exon is depicted as a separate box consisting of white box indicating untranslated 
region and the gray portion representing the translated region. Translation initiation site (ATG) is located 
at the start of the gray portion.  
 
 
 
 
* 
* 
bp 
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Results  
1. Optimization of custom MS-MLPA test using cell lines 
 
Six synthetic MS-MLPA probe pairs were designed for four genes (HNF1B, L1CAM 
CpG islands I and II, TET1, and ARID1A, CpG islands 4 & 5) according to the 
manufacturer’s instructions (MRC-Holland, Amsterdam). DNA methylation patterns of 
20 cell lines, including 15 cancer cell lines and 5 normal cell lines and DNAs, were 
analyzed by this custom-designed MS-MLPA test. For optimization of MS-MLPA test, 
DNAs of 20 cell lines were first bisulfite sequenced. After performing custom-made MS-
MLPA test on these cell lines, the bisulfite sequencing results were compared with those 
of MS-MLPA test. After proving the correlation between bisulfite sequencing and MS-
MLPA results, the test was applied to the clinical samples. A detailed description of 
results from each step will follow.   
To validate the accuracy of the custom-designed MS-MLPA kit in DNA methylation 
detection, bisulfite sequencing was carried out. In each studied promoter region, the DNA 
methylation patterns of several CpG sites were analyzed by bisulfite sequencing. The 
CpG site containing the restriction site (GCGC) for the HhaI enzyme in the corresponding 
MS-MLPA test should ideally represent the DNA methylation pattern of the whole 
region. DNA methylation status of one colorectal cancer cell line (RKO) detected by 
bisulfite sequencing and MS-MLPA test is presented in Figure 8.  
As displayed in Table 7, the bisulfite sequencing results from normal and cancer cell lines 
were compared with those of custom-made MS-MLPA test. The purpose of comparing 
bisulfite sequencing vs. MS-MLPA results of the cell lines was to determine the technical 
threshold value for a reliable detection of methylation. Based on data shown in Table 7, 
the technical threshold was set at 0.20. When the methylation dosage ratio was ≥ 0.20, 
the cell lines were considered to be methylated. The cell lines with a methylation dosage 
ratio lower than 0.20 were interpreted to be unmethylated. Twenty cell lines were used 
for DNA methylation analysis, including 4 ovarian cancer cell lines, 7 CRC cell lines, 3 
breast cancer cell lines, and 5 normal cell lines and DNAs. In Table 7, the presence of C 
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and T bases in the bisulfite sequencing tracing are indicated as C and T, respectively. If a 
heterogenous pattern of both C and T bases were present in bisulfite sequencing, this is 
shown as C/T or T/C, where the base with the highest peak is written first.  
As presented in Table 7, MS-MLPA results were in agreement with the bisulfite 
sequencing results. All cell lines that showed methylation (C indicates methylation) by 
bisulfite sequencing were also shown to be methylated by MS-MLPA with a variation of 
Dm between 0.28 (L1CAM gene, island II in AN3CA cell line) to 1.16 (L1CAM I gene, 
island I in HCA7cell line). As the cut-off limit was set at 0.20 in MS-MLPA test, all cell 
lines that were unmethylated (T indicates unmethylation) by bisulfite sequencing, also 
showed to be unmethylated by MS-MLPA. In unmethylated CpG sites, the methylation 
ratio varied between 0 (In the vast majority of cell lines in TET1 gene, ARID1A gene, 
island 4 & 5) to 0.18 (ARID1A gene, island 4 in KM12 cell lines). 
If the studied CpG sites showed a heterogenous pattern of both C and T by bisulfite 
sequencing, the methylation dosage ratios by MS-MLPA varied between 0.20 (L1CAM 
gene, island II, normal uterus blood sample) to 0.69 (L1CAM gene, island I, SPR.198 
blood sample; however  the methylation ratios were not lower in the sites interpreted as 
T/C compared to C/T. Heterozygous sites (C/T & T/C) in bisulfite sequencing results 
were interpreted as methylated by MS-MLPA test.   
The ARID1A gene (both island 4 and 5) was unmethylated in all cancer cell lines and 
normal samples. The TET1 gene was also unmethylated in most of the cancer cell lines 
and all normal samples. Three colorectal cancer cell lines, including KM12, RKO, and 
HCT15 were methylated in the TET1 gene. The HNF1B gene was methylated in the 
majority of the cancer cell lines and is shown to be unmethylated in all normal samples. 
The L1CAM gene island I was methylated in all cancer cell lines (except CAOV3) and 
normal samples, and the methylation dosage ratios by MS-MLPA were higher in cancer 
cell lines compared to normal samples. The L1CAM gene island II was methylated in the 
majority of the cancer cell lines and normal samples and the methylation dosage ratios 
did not differ much between methylated cancer cell lines and normal samples. 
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Figure 8.  Bisulfite sequencing and MS-MLPA results of the colorectal cancer cell line RKO.  (a) The CpG island studied by bisulfite sequencing in L1CAM island II 
contained 20 CpG sites, including one recognition site (GCGC) for the methylation-sensitive recognition enzyme HhaI (CpG sites are numbered and GCGC site is shown with 
arrow). As it can be seen, most of the CpG dinucleotides are methylated (C indicates methylation status), including the CpG site 19 analyzed later by MS-MLPA. (b) The top 
picture is the MS-MLPA results without HhaI treatment. The lower panel is after digestion with HhaI, resulting in peaks for control probes and methylated CpG sites. No peaks 
for unmethylated CpG sites are presented.  (   : control peaks, D: fragment peaks). 
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 Table 7. The comparison of methylation status acquired by bisulfite sequencing and MS-MLPA. 
 
 
 
Cell line  
 
 
 
Cell type  
HNF1B 
Bisulfite 
sequencing 
(GCGCsite*) 
HNF1B 
MS-MLPA 
(Dm) 
L1CAMI 
Bisulfite 
sequencing 
(GCGC site) 
L1CAMI 
MS-MLPA 
(Dm) 
L1CAMII 
Bisulfite 
sequencing 
(GCGC site) 
L1CAMII 
MS-MLPA 
(Dm) 
ES2  
OV4   
SKOV3  
CAOV3   
AN3CA 
HCA7    
KM12 
RKO   
T84  
HCT15 
HCT116  
SW480   
BT-549  
CAL-51     
ZR-75-1    
MCF-12A   
TKF 
SPR.198  
Normal uterus    
Normal colon                                                                             
Ovary, clear cell adenocarcinoma     
Ovary, serous adenocarcinoma    
Ovary, serous adenocarcinoma    
Ovary, serous adenocarcinoma    
Uterus/endometrium adenocarcinoma     
High methylator colorectal carcinoma 
Colon, adenocarcinoma      
High methylator colorectal carcinoma  
Colon, colorectal carcinoma  
High methylator colorectal carcinoma 
Colon, colorectal carcinoma    
Colorectal adenocarcinoma  
Hypermethylator breast cancer cell 
Breast cancer cell with MSI 
Low methylator breast cancer cell       
Normal breast epithelial cells    
Blood  
Blood    
Epithelial 
Epithelial        
C/T 
C 
T 
C 
C 
T 
C 
C 
T 
T 
C 
C 
T/C 
T 
C 
C 
T 
T 
T 
T 
0.43 
0.73 
0 
0.92 
0.76 
0 
0.88 
0.91 
0 
0 
0.52 
0.66 
0.44 
0 
0.58 
0.29 
0.03 
0.05 
0 
0 
C 
C 
C 
T 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C/T 
C/T 
C/T 
C/T 
1.02 
1.03 
1.08 
0 
1.09 
1.16 
0.97 
1.00 
1.05 
1.03 
1.02 
0.86 
1.00 
0.95 
0.76 
0.92 
0.54 
0.69 
0.55 
0.44 
C/T 
C 
C 
T 
C 
T 
C 
C 
T 
C 
T 
T 
T 
C 
C/T 
C 
C/T 
T/C 
C/T 
T 
0.17 
0.41 
0.38 
0 
0.28 
0.04 
0.30 
0.91 
0 
1 
0 
0.02 
0.04 
0.42 
0.32 
0.44 
0.24 
0.24 
0.20 
0 
*In regard to bisulfite sequencing, the status of the CpG-dinucleotide-associated cytosine (GCGC) is indicated. 
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Cell line  
 
 
 
 
Cell type  
TET1 
Bisulfite 
sequencing 
(two 
*GCGCsites) 
TET1 
MS-MLPA 
(Dm) 
ARID1A 5 
Bisulfite 
sequencing 
(GCGC site) 
ARID1A 5 
MS-MLPA 
(Dm) 
ARID1A 4 
Bisulfite 
sequencing 
(GCGC site) 
ARID1A 4 
MS-MLPA 
(Dm) 
ES2  
OV4   
SKOV3  
CAOV3   
AN3CA 
HCA7    
KM12 
RKO   
T84  
HCT15 
HCT116  
SW480   
BT-549  
CAL-51     
ZR-75-1    
MCF-12A   
TKF 
SPR.198  
Normal uterus    
Normal colon                                                                             
Ovary, clear cell adenocarcinoma     
Ovary, serous adenocarcinoma    
Ovary, serous adenocarcinoma    
Ovary, serous adenocarcinoma    
Uterus/endometrium adenocarcinoma     
High methylator colorectal carcinoma  
Colon, adenocarcinoma      
High methylator colorectal carcinoma  
Colon, colorectal carcinoma  
High methylator colorectal carcinoma  
Colon, colorectal carcinoma    
Colorectal adenocarcinoma  
Hypermethylator breast cancer cell 
Breast cancer cell with MSI 
Low methylator breast cancer cell       
Normal breast epithelial cells    
Blood  
Blood    
Epithelial 
Epithelial        
T&T 
T&T 
T&T 
T&T 
T&T 
T&T 
C&C 
C&C 
T&T 
C&C 
T&T 
T&T 
T&T 
T&T 
T&T 
T&T 
T&T 
T&T 
T&T 
T&T 
0 
0 
0 
0 
0 
0 
0.49 
0.38 
0 
0.36 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
0 
0 
0 
0 
0 
0 
0.08 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.04 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
0 
0 
0 
0 
0 
0 
0.18 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
*In regard to bisulfite sequencing, the status of the CpG-dinucleotide-associated cytosine (GCGC) is indicated.
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2. Hypermethylation in precursor lesions of endometrial carcinoma 
 
Methylation in the HNF1B, L1CAM (island I & II), ARID1A (island 4 &5), and TET1 
genes was studied in 79 precursor lesions of endometrial carcinoma (23 sporadic complex 
hyperplasia, 19 sporadic complex atypical hyperplasia, 17 sporadic simplex hyperplasia) 
and 18 normal endometrium tissues using MS-MLPA test. The cut-off Dm values for 
hypermethylation relative to normal endometrium were determined as described in 
Material and methods (p.39). Gene-specific thresholds and their derivation are shown in 
Table 8. The HNF1B, TET1 and ARID1A genes showed low mean methylation dosage 
ratios in the normal endometrium tissues and the technical threshold (0.20) also served as 
the threshold for hyper-methylation. For L1CAM gene, the cut-off level of 
hypermethylation was (0.59 for island I and 0.39 for island II) calculated using the mean 
methylation dosage ratio, Dm, from all normal tissues + 1 standard deviation.  
 
Table 8. Gene-specific thresholds for hypermethylation for samples with normal endometrium as the 
reference tissue (endometrial hyperplasias, and endometrioid and clear cell ovarian cancers). 
 
Normal endometrium 
HNF1B TET1 L1CAM 
 I 
L1CAM 
II 
ARID1A 
4 
ARID1A 
5 
01- Secretory 
02- Secretory 
03- Secretory 
04- Secretory 
05- Secretory 
06- Secretory 
07- Secretory 
08- Secretory 
09- Secretory 
10- Proliferatory 
11- Proliferatory 
12- Proliferatory 
13- Proliferatory 
14- Proliferatory 
15- Proliferatory 
16- Proliferatory 
17- Proliferatory 
18- Proliferatory 
Mean methylation dosage (x̄) 
SD 
x̄+1SD 
Cut-off value for hypermethylation  
0.07 
0.06 
0.05 
0.10 
0.13 
0.08 
0.03 
0.05 
0.08 
0.00 
0.07 
0.08 
0.09 
0.10 
0 
0.05 
0.02 
0 
0.06 
0.04 
0.10 
0.20* 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.20* 
0.73 
0.56 
0.49 
0.51 
0.42 
0.44 
0.39 
0.48 
0.48 
0.56 
0.56 
0.54 
0.47 
0.55 
0.44 
0.33 
0.52 
0.20 
0.48 
0.11 
0.59 
0.59 
0.35 
0.34 
0.41 
0.3 
0.37 
0.31 
0.25 
0.3 
0.32 
0.33 
0.36 
0.29 
0.29 
0.47 
0.26 
0.33 
0.18 
0.12 
0.31 
0.08 
0.39 
0.39 
0.03 
0 
0.05 
0.04 
0.07 
0.06 
0.02 
0 
0 
0 
0 
0 
0.05 
0.06 
0.04 
0 
0 
0 
0.02 
0.03 
0.05 
0.20* 
0.09 
0 
0 
0.05 
0 
0 
0.05 
0 
0 
0.18 
0 
0 
0 
0.05 
0 
0 
0 
0 
0.02 
0.05 
0.07 
0.20* 
* Represents the technical threshold (Material and methods, p.39) 
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Methylation results of endometrial hyperplasias are shown in two alternative ways below, 
as average Dm values (based on absolute Dm values given by MS-MLPA, Fig.9A) and 
as percentages of samples with hypermethylation (only samples with Dm values equal to 
or higher than cut-off values specified in Table 8 were counted as hypermethylated, 
Fig.9B). Figure 9B also gives results from statistical testing. In TET1 and ARID1A DNA 
methylation was not practically observed at all in either normal endometrium or 
hyperplasia cases. HNF1B showed slightly elevated methylation in hyperplasias. For 
L1CAM, there was an increasing trend for methylation (Fig. 9A) and especially 
hypermethylation (Fig. 9B) from normal endometrium to simplex hyperplasia to complex 
hyperplasia without atypia to complex hyperplasia with atypia. Compared to normal 
endometrium, all types of endometrial hyperplasia showed significantly higher 
frequencies of hypermethylation for L1CAM I (Fig. 9B). The same was true with complex 
hyperplasia with atypia for L1CAM II. The remaining comparisons indicate no formal 
statistical significance.  
 
 
 
Figure 9A. The average Dm values for endometrial hyperplasias and normal endometrium shown 
separately for each gene. 
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Figure 9B. Frequencies of hypermethylation for endometrial hyperplasias and normal endometrium using 
gene-specific cut-off indicated in Table 8. Pairwise comparisons were calculated by Fisher Exact test (two-
sided P values). P values < 0.05 were considered significant. NS= Not statistically significant. 
 
3. Hypermethylation in clinical sporadic ovarian carcinoma samples 
 
MS-MLPA was used to profile DNA methylation status of HNF1B, L1CAM (island I & 
II), ARID1A (island 4 &5), and TET1 gene in sporadic ovarian carcinomas. The clinical 
samples comprised sporadic ovarian cancer of the clear cell (n = 35), endometrioid (n = 
24), and serous types (n = 20). It has been proposed that non-serous tumors (endometrioid 
and clear cell tumors) arise from endometrium and serous tumors arise from the fallopian 
tube, which was taken into account in the calculation of the threshold for 
hypermethylation. To have an optimal discrimination between normal and tumor tissues, 
the hypermethylation thresholds were calculated using the mean Dm in normal 
endometrium (for non-serous samples, Table 8 above) and normal fallopian tubes (for 
serous tumors, Table 9) plus 1 standard deviation. For genes with value lower than the 
technical threshold (0.20), the latter was used as the threshold for hypermethylation 
(similar to endometrial lesions described in the previous section). 
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Fisher Exact test, pairwise comparisons                                           L1CAMI   L1CAMII   HNF1B   TET1   ARID1A, 4 ARID1A, 5
Normal endometrium-Sporadic simplex hyperplasia                         < 0.001 NS          NS         NS          NS             NS
Normal endometrium- Sporadic complex hyperplasia                      < 0.001 0,075      NS          NS          NS             NS
Normal endometrium-Sporadic complex hyperplasia with atypia  < 0.001 0,029      NS        NS         NS             NS
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Table9. Gene-specific thresholds for hypermethylation for samples with normal fallopian tubes as 
the reference tissue (serous ovarian cancer). 
Normal fallopian tube HNF1B TET1 L1CAM 
I 
L1CAM 
II 
ARID1A 
4 
ARID1A 
5 
01-Normal fallopian tube 
02-Normal fallopian tube 
03-Normal fallopian tube 
04-Normal fallopian tube 
05-Normal fallopian tube 
06-Normal fallopian tube 
07-Normal fallopian tube 
08-Normal fallopian tube 
09-Normal fallopian tube 
10-Normal fallopian tube 
11-Normal fallopian tube 
12-Normal fallopian tube 
13-Normal fallopian tube 
14-Normal fallopian tube 
Mean methylation dosage (x̄) 
SD 
x̄+1SD 
Cut-off value for hypermethylation  
0.09 
0.15 
0.08 
0.09 
0.15 
0.18 
0.23 
0.06 
0.07 
0.13 
0.07 
0.12 
0.11 
0.09 
0.12 
0.05 
0.17 
0.20* 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.07 
0 
0 
0 
0.17 
0.02 
0.05 
0.07 
0.20* 
0.3 
0.37 
0.39 
0.39 
0.64 
0.54 
0.49 
0.3 
0.28 
0.45 
0.4 
0.48 
0.4 
0.54 
0.43 
0.10 
0.53 
0.53 
0.26 
0.23 
0.2 
0.3 
0.16 
0.18 
0.1 
0.3 
0.2 
0.4 
0.28 
0.33 
0.38 
0.34 
0.26 
0.08 
0.34 
0.34 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.05 
0 
0 
0.05 
0 
0.01 
0.02 
0.03 
  0.20* 
0 
0 
0 
0.05 
0 
0 
0 
0 
0 
0 
0 
0 
0.04 
0.06 
0.01 
0.02 
0.03 
  0.20* 
* Represents the technical threshold (Material and methods, p.39). 
 
 
DNA methylation profiles for non-serous tumors are shown in Figures 10A and B. TET1 
and ARID1A showed little methylation in normal endometrium and tumor tissues; among 
these genes, clear cell carcinoma with a 22% rate of hypermethylation for TET1 provided 
the strongest evidence of altered methylation (Fig. 10B). Increased methylation was more 
common for L1CAM and HNF1B (Figs. 10A & 10B). In HNF1B and L1CAM II an 
increasing trend for hypermethylation was observed from normal endometrium to clear 
cell to endometrioid tumors (Fig. 10B).  
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Figure 10A. The average of Dm values in sporadic non-serous ovarian tumors and normal endometrium. 
 
 
 
 
Figure 10B. Frequencies of hypermethylation for sporadic non-serous ovarian tumors and normal 
endometrium using gene-specific cut-off indicated in Table 8. Pairwise comparison were calculated by 
Fisher Exact test (Two-sided P values). P values < 0.05 were considered significant. NS= Not statistically 
significant. 
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DNA methylation results for serous tumors are displayed in Figures 11A and 11B. For 
TET1 and ARID1A, methylation was relatively rare in normal fallopian tubes and serous 
tumors (Fig. 11A & 11B). HNF1B and L1CAM II were frequently hypermethylated (25% 
& 35%, respectively) in serous samples compared to normal fallopian tubes (7% &14%, 
respectively, Fig. 11B). For L1CAMI, the frequency of hypermethylation in normal 
fallopian tubes exceeded that in serous tumors (Fig. 11B). Compared to normal fallopian 
tubes, serous tumors were not associated with significantly higher frequencies of 
hypermethylation for any studied genes.  
Figure 11A. The average of Dm values in sporadic serous ovarian tumors and normal fallopian tubes.  
 
Figure 11B. Frequencies of hypermethylation in sporadic serous ovarian tumors and normal fallopian tubes 
using gene-specific cut-off indicated in Table 9. Pairwise comparison were calculated by Fisher Exact test 
(Two-sided P values). P values < 0.05 were considered significant. NS= Not statistically significant. 
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Discussion 
1. Methylation status of the selected genes in cell lines 
 
Our collection included four ovarian cancer cell lines, three of serous and one of clear 
cell origin (Table 1). HNF1B was completely methylated in 2/3 serous ovarian cancers 
and regarding the single unmethylated one (SKOV3), serous origin has been questioned 
(Niskakoski et al., 2014). The clear cell carcinoma (ES-2) showed partial methylation. 
HNF1B was completely unmethylated in normal sample DNAs. HNF1B was also 
completely methylated in 57% (4/7) of CRC cell lines, and completely unmethylated in 
normal cells. Our findings for the methylation status of HNF1B in cancer cell lines is in 
line with Terasawa et al. findings in 2006. They studied the methylation status of HNF1B 
gene in the SKOV3, CAOV3, RKO, HCT116, SW480 cell lines, and normal (colon and 
ovarian) samples using COBRA and bisulfite sequencing. HNF1B was methylated in the 
ovarian cancer cell lines in a histology specific pattern, resulting in loss of the gene’s 
expression (observed in the same region as in this study).  
The methylation level of L1CAM was higher in ovarian, colon, and breast cancer cell 
lines compared to normal samples. Kato et al, (2009) reported that L1CAM is methylated 
in 50% of CRC cell lines (2 of 4) and in 43.7% of primary CRCs (31 of 71 cases), which 
is in agreement with our results. In our study, of 7 CRCs cell lines, 3 (57.14%) were 
methylated. 
ARID1A (Island 4 and 5) was unmethylated in both cancer cell lines and normal samples. 
We are not aware of any published methylation data for ARID1A regarding the same cell 
lines we studied. TET1 was methylated in 43% (3/7) of CRC cell lines but completely 
unmethylated in normal samples. Our findings of TET1 methylation are in line with 
Ichimura et al. (2015) and Li et al. (2016) results. They studied the DNA methylation 
status of SW480, RKO, HCT116, HCT15, T84, MCF-7, ZR-75-1 cell lines using 
pyrosequencing and MSP. The TET1 was methylated in RKO and HCT15 whereas it 
showed to be unmethylated in the rest of cancer cell lines and normal cell lines and DNAs.   
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2. Hypermethylation in endometrial lesions 
 
We performed the DNA methylation analysis of the selected genes in lesions of the 
endometrium (simplex hyperplasia, complex hyperplasia without atypia and complex 
hyperplasia with atypia) using MS-MLPA approach. Normal endometrium tissues were 
used as a reference group. In endometrial hyperplasia series, methylation of L1CAM was 
increasingly hypermethylated along with histological abnormality (from simplex 
hyperplasia to complex hyperplasia to complex atypical hyperplasia, Fig.9B). This result 
is in line with the finding of Nieminen et al. (2009) and Joensuu et al. (2015) where the 
promoter DNA methylation of TSGs and the methyltransferase protein expression, 
respectively, increased with histological abnormality (observed in the same endometrial 
hyperplasia samples as in this study). 
The increasing trend of methylation along with histological abnormality was observed in 
L1CAM gene in both island I and II (in L1CAMI, the frequency of hypermethylation in 
complex atypical hyperplasia is 4 % lower than that of in complex hyperplasia). Schirmer 
et al. in 2013 reported that L1CAM protein was absent in the vast majority of 
endometrioid endometrial carcinoma. It is proposed that endometrial hyperplasia can 
develop to endometrioid endometrial carcinoma. Since L1CAM expression has been 
shown to be inversely correlated with methylation of promoter I (Schirmer et al., 2013), 
our observation of hypermethylation of L1CAM in endometrial hyperplasia is in line with 
the reported absence of its expression in endometrioid endometrial carcinoma.  
In our study, HNF1B showed low frequencies of hypermethylation in endometrial 
hyperplasias. Nemejcova et al (2016) studied the protein expression status of HNF1B in 
hyperplasia with atypia and hyperplasia without atypia. They detected expression of 
HNF1B in 88% of hyperplasias with atypias (14/16 cases), and 91% of hyperplasias 
without atypias (10/11cases). As it has been identified that the expression of HNF1B is 
inversely controlled by DNA methylation, our findings in HNF1B are in close 
concordance with this study.  In TET1 and ARID1A, no methylation was detected in any 
histotypes of endometrial lesions.  
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3. Hypermethylation in sporadic ovarian carcinomas 
 
We examined promoter methylation by the MS-MLPA method in 79 sporadic ovarian 
carcinomas of different histological types, using normal (unrelated) endometrium and 
normal (unrelated) fallopian tube tissues, as references.  
Terasawa et al. (2006) reported that HNF1B was methylated in 41% of serous samples, 
25% of mucinous tumors, and 29% of endometrioid tumors. There was no methylation in 
clear cell samples and normal ovarian endometrium tissues. In our study, the frequency 
of samples with hypermethylation increased from normal endometrium (0%) to normal 
fallopian tubes (7%) to clear cell (6%) to endometrioid (17%) and to serous samples 
(25%), which is in agreement with the report by Terasawa et al. in 2006. Since an inverse 
correlation of DNA methylation and protein expression has been identified in HNF1B 
(Terasawa et al. 2006) and HNF1B is shown to have different patterns of methylation 
between CCCs and non-CCCs, this gene can be used as a good marker of clear cell 
phenotype. 
L1CAMI revealed low frequencies of hypermethylation in serous (20%) compared to 
endometrioid (46%) and clear cell ovarian carcinoma (58%). In terms of methylation 
dosage ratios, L1CAMI showed reduced methylation in serous ovarian carcinoma vs. 
normal fallopian tube (average Dm was 0.37 vs.0.43, respectively). Importantly, the 
average Dm in serous ovarian carcinoma was clearly lower than in endometrioid (0.55) 
and clear cell (0.58) ovarian carcinomas. These findings are in agreement with 
observation of high L1CAMI expression being characteristic of high-grade serous ovarian 
carcinoma (Bondong et al., 2012), under the assumption that expression and methylation 
are inversely correlated (Schirmer et al., 2013). DNA hypermethylation was not observed 
in TET1 at all, except in clear cell samples (22%).  
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4. Methodological aspects  
 
DNA methylation status can be studied by a variety of different methods. Most of the 
common methods are based on bisulfite treated DNA, are time and work consuming, and 
often require good quality DNA. We chose the MS-MLPA method to analyze methylation 
mainly because it turned out to be suitable for paraffin embedded tissues. MS-MLPA is 
based on a methylation-specific endonuclease, does not use bisulfite converted DNA, and 
requires only 20ng of DNA. MS-MLPA approach was easy to learn and easy to perform. 
The custom-made MS-MLPA analysis can be considered to be a reliable approach to 
evaluate DNA methylation status in ovarian and endometrial carcinomas because there 
was a nearly complete agreement between bisulfite sequencing results and MS-MLPA 
results.  
 
 
5. Conclusions and future prospects 
 
In this research we analyzed the promoter DNA methylation status of four genes (HNF1B, 
L1CAM, TET1, and ARID1A) in ovarian carcinoma and precursor lesions of endometrial 
carcinoma. We found that HNF1B and L1CAM showed differential promoter 
methylation depending on the histological subtype of cancer. TET1 was methylated in 
clear cell carcinomas only. L1CAM showed an increasing trend in hypermethylation in 
endometrial precursor lesions (from normal endometrium to simple hyperplasia to 
complex hyperplasia without atypia to complex hyperplasia with atypia). Overall, our 
findings in this research are in line with existing literature, when available, and provide 
new information of the role of altered DNA methylation in endometrial and ovarian 
tumorigenesis. 
This study focused on cell lines and sporadic samples of endometrial hyperplasias and 
ovarian cancer. One remaining task of interest is to study differences and similarities in 
DNA methylation, when ovarian cancers from the Lynch syndrome families are 
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compared with sporadic ovarian cancers. In addition, we would be interested to assess the 
DNA methylation status and other molecular alterations, when the precursor lesions of 
endometrial cancer with MMR gene mutation are compared with the sporadic series of 
endometrial specimens studied here. Lynch syndrome offers the advantage to examine 
consecutive endometrial specimens (because MMR mutation carriers participate in a 
regular surveillance by endometrial biopsies) as well as multiple cancers (endometrial 
and ovarian) developing in a single individual. Therefore, the custom-designed MS-
MLPA test will be used in the future to analyze DNA methylation patterns in Lynch 
syndrome-associated ovarian and endometrial cancer.  
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